Aurobindo Pharma shares fall 3% after Q2 earnings

New Delhi: Shares of Aurobindo Pharma Tuesday fell almost 3 per cent after the company reported 21.70 per cent dip in consolidated net profit for the quarter ended September 30, 2018. The stock went down 2.96 per cent to end at Rs 774.70 on BSE. During the day, it declined 4.76 per cent to Rs 760.25.

On NSE, shares of the company dropped 2.63 per cent to close at Rs 775.

Aurobindo Pharma Monday reported 21.70 per cent dip in consolidated net profit to Rs 611.44 crore for the September quarter, mainly on account of rise in expenses.

The company had posted a net profit of Rs 780.97 crore in the year-ago period, Aurobindo Pharma said in a BSE filing.

Consolidated total revenue from operations stood at Rs 4,751.40 crore for the quarter under review. It was Rs 4,435.89 crore in the same period last year.

Total expenses stood at Rs 3,964.20 crore for the reported quarter. It was Rs 3,468.36 crore during the same period of 2017-18.

  • Related Posts

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?